Select Language:
EnglishEspaņol
Adjust Text Size:
change font sizechange font sizechange font sizechange font sizechange font sizechange font size

Browse Clinical Trials


Join the Email List

Sign up for our email bulletin

Go

Participant Stories

“I participate because it is the right thing to do, for myself, for my children, and for the millions of people who have Parkinson’s disease.  Without participation there will be no cure.” –Mike, Diagnosed 7 years

Read More

Recently Diagnosed with Parkinson's Disease?

If you have recently been diagnosed with Parkinson’s disease (PD) understanding the disease, and learning about the resources available to you, are good first steps.

Learn More

Neuroimaging Studies of Depression in Parkinson's Disease

Official Study Title: UK/VA Neuroimaging  NeuroimagingNon-invasive techniques (e.g. computed tomography, magnetic resonance imaging, and positron-emission tomography) for measuring brain structure and function that may reveal important insights into aspects of PD not directly related to biomarkers and treatment trials. Studies of Depression in Parkinson's Disease
Sponsor: University of Kentucky (NIMH, NINDS)
Clinicaltrials.gov ID: NCT00518258
Study ID: R01-MH78228-2

Summary

Depression is a common and potentially serious complication of Parkinson's disease  Parkinson's DiseaseA chronic, slowly progressive disease of the nervous system characterized by the combination of tremor, rigidity, bradykinesia and stooped posture, among other symptoms. (PD). Studies show that approximately 40 percent of people with PD are depressed. There is evidence that these people have deficits in neuropsychological function relative to people with PD who are not depressed. Despite the widespread toll on emotional health posed by PD, few studies have undertaken a comprehensive examination of the neural underpinnings of Parkinsonian depression. In this project, the researchers will compare depressed versus non-depressed participants with PD to demographically-matched healthy people using neuropsychological assessment and magnetic resonance imaging  Magnetic Resonance Imaging (MRI)A non-invasive technique that uses magnetism to create detailed pictures of the inside of the human body. (MRI). To investigate possible effects of anti-Parkinsonian medication on mood, cognitive  CognitiveRelated to mental activities having to do with perception, memory, judgment, and reasoning. function, and neural response, participants with PD will be tested both off and on Parkinsonian medications.

Study Phase

Not Specified
What is a study phase?

Symptoms Addressed: Non-movement Symptoms

Depression

Time Commitment

  • Less than six months
  • Participants come to the University of Kentucky 3 times over about a month. Each visit will last 3 - 5 hours.

Eligibility

  • Minimum Age: 40
  • Maximum Age: 85
  • Gender(s) Accepted: Either
  • Study is enrolling non-PD participants

Inclusion Criteria

  • Right-handed
  • Willing/able to undergo magnetic resonance imaging (MRI)

Exclusion Criteria

  • History of neurological condition other than PD
  • History of psychiatric condition other than depression
  • History of substance abuse/dependence
  • Current use of psychiatric medication

Enrollment

Expected Enrollment: 120 (US)
Date Enrollment Began: Jul 2006
Date Enrollment Ends: Jun 2011
Last Updated Date: May 06 2011
Trial Post Date: Nov 07 2007
Website: http://clinicaltrials.gov/ct/show/NCT00518258?order=1

Primary Contacts and Locations

Kentucky

  • Chris Miara — Trial Coordinator
    University of Kentucky
    mcmiar00@uky.edu
    Phone: 859-257-9223 x2
    Lexington, KY 40536
    USA